Abstract
Cisplatin-based combined chemoradiotherapy is now the standard of treatment for locally advanced cervical cancer. Although combined-modality treatment has improved survival, it has also increased the already high frequency of toxicity observed with traditional radiotherapy alone. Cervical cancer patients with para-aortic metastasis may be at particularly high risk of toxicity with combined-modality treatment. The few clinical trial data available on the use of amifostine in cervical cancer or pelvic cancer patients suggest benefit in reducing treatment toxicity. The potential role of amifostine in combination with currently used cisplatin-based chemoradiotherapy regimens is being assessed in a Radiation Therapy Oncology Group phase I/II study in cervical cancer patients with positive para-aortic or high common iliac lymph nodes. Semin Oncol 29 (suppl 19):34-37. Copyright 2002, Elsevier Science (USA). All rights reserved.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
